News

June 14, 2017June 14, 2017

Update on FOCUS Trial of CA4P in Ovarian Cancer Expected in Late Summer

News

Second preliminary results from the FOCUS Phase 2/3 trial assessing the safety and effectiveness of Mateon Therapeutics’ drug candidate CA4P in combination with standard-of-care therapies for platinum-resistant ovarian cancer are expected ... Read more

June 12, 2017June 12, 2017

Siamab to Present Preclinical Data for ST1 Antibody Drug Conjugates at 2017 BIO International Convention

News

Siamab Therapeutics will present new preclinical data on the safety and efficacy of its flagship ST1 antibody drug conjugates program in ovarian cancer animal models at the 2017 BIO International ... Read more

June 9, 2017June 9, 2017

Better Delivery Method Sought for High-dose Chemo Known to Treat Residual Ovarian Cancer

News

A recent study aimed to define the most effective chemotherapy dosage to successfully shrink tumors after surgery in women with residual ovarian cancer spread throughout the abdomen. It found that the ... Read more

June 7, 2017June 7, 2017

Lynparza Prolongs Progression-Free Survival, Sustains Quality of Life in Women with BRCA-Mutated Relapsed Ovarian Cancer

News

Women with BRCA-mutated relapsed serous ovarian cancer who received AstraZeneca’s Lynparza (olaparib) as a maintenance therapy after responding to platinum-based chemotherapy took an average 14 months to see their disease progress, compared to 7.3 ... Read more

June 6, 2017June 6, 2017

Several Studies on Track for Ovarian and Breast Cancer Vaccine TPIV 200

News

The Phase 2 trial evaluating the combination of the TPIV 200 cancer vaccine with the immune checkpoint inhibitor Imfinzi (durvalumab) in ovarian cancer patients who progressed after receiving platinum-based chemotherapy ... Read more

June 2, 2017June 2, 2017

Blood Sugar and GLUT1 Protein May Be Biomarkers for Ovarian Cancer, Study Finds

News

Researchers studying blood glucose levels and the glucose transporter protein GLUT1 have discovered a potential biomarker for aggressive ovarian cancer. A study found that patients with lower blood glucose levels ... Read more

May 31, 2017

Zejula Continues to Show Promise in Recurrent Ovarian Cancer Patients

News

Tesaro will present three abstracts with results from the ENGOT-OV16/NOVA trial evaluating the effectiveness of Zejula (niraparib) in patients with recurrent ovarian cancer at the upcoming 2017 American Society of Clinical ... Read more

May 26, 2017

Oregovomab Combo Benefits Ovarian Cancers More Than Chemo Alone, Study Reports

News

Adding oregovomab to standard chemotherapy significantly increases the time it takes for a newly diagnosed advanced ovarian cancer patient to have their disease progress or die, according to a Phase ... Read more

May 24, 2017

Most Ovarian Cancer Patients Want Doctors to Discuss the Unknowns, Survey Indicates

News

Sixty-four percent of ovarian cancer patients are concerned enough about their path forward that they want doctors to discuss the unknowns of the disease with them, according to a survey ... Read more

May 22, 2017

ImmunoGen’s Investigative Therapy for Ovarian Cancer Shows Potential in Clinical Studies

News

ImmunoGen will show promising safety and efficacy data of its investigative treatment mirvetuximab soravtansine for the treatment of FRα-positive epithelial ovarian cancer (EOC). The positive top-line data will be presented in three poster ... Read more